Home > Insider Trading > Filing (0001455244-10-000034)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
72444	Nabi Biopharmaceuticals	NABI	Biological Products, (No Disgnostic Substances) (2836)	591212264

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1459477	W. Matthew Kalnik	8610 Fernwood Road Bethesda MD 20817	Svp Strategic Plan. & Bus. Ops	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2009-11-30	5,404	$2.41	39,523	No	5	J	Direct
Common Stock	Acquisiton	2010-03-02	2,250	$3.95	41,773	No	4	M	Direct
Common Stock	Disposition	2010-03-02	2,250	$5.45	39,523	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	5	J	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2010-03-02	2,250	$0.00	2,250	$3.95

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
15,750		2015-04-01	No	4	M	Direct

Footnotes

Voluntarily reported acquisition under the Issuer's Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3.
The acquisition and sale of 2,250 shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
One-quarter of this Option became exercisable on April 1, 2009. The remaining three-quarters of the Option will become exercisable in three equal installments on April 1, 2010, April 1, 2011 and April 1, 2012.